Vera Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vera Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Vera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$33.7M, a 67.2% decline year-over-year.
  • Vera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$108M, a 0.47% decline year-over-year.
  • Vera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$96M, a 7.79% decline from 2022.
  • Vera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$89.1M, a 173% decline from 2021.
  • Vera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$32.6M, a 38.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$108M -$33.7M -$13.5M -67.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$94.3M -$28.4M +$1.69M +5.61% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-08
Q4 2023 -$96M -$25.7M +$6.78M +20.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$103M -$20.1M +$4.58M +18.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$107M -$20.2M -$5.31M -35.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$102M -$30.1M -$13M -76% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-08
Q4 2022 -$89.1M -$32.4M -$15.6M -92.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 -$73.5M -$24.7M -$17.1M -224% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$56.4M -$14.9M -$11.4M -332% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$45M -$17.1M -$12.4M -262% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$32.6M -$16.8M +$26M +60.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-28
Q3 2021 -$58.6M -$7.61M -$3.15M -70.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$55.5M -$3.44M +$167K +4.63% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$55.7M -$4.71M -$2.24M -90.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$53.4M -$42.9M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$4.46M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$3.6M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$2.47M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.